- Home
- EDD vs PRQR Comparison
EDD vs PRQR Comparison
Compare EDD & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDD
- PRQR
- Stock Information
- Founded
- EDD 2007
- PRQR 2012
- Country
- EDD United States
- PRQR Netherlands
- Employees
- EDD N/A
- PRQR N/A
- Industry
- EDD Finance Companies
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- EDD Finance
- PRQR Health Care
- Exchange
- EDD Nasdaq
- PRQR Nasdaq
- Market Cap
- EDD 304.3M
- PRQR 309.5M
- IPO Year
- EDD N/A
- PRQR 2014
- Fundamental
- Price
- EDD $4.61
- PRQR $3.61
- Analyst Decision
- EDD
- PRQR Strong Buy
- Analyst Count
- EDD 0
- PRQR 4
- Target Price
- EDD N/A
- PRQR $7.13
- AVG Volume (30 Days)
- EDD 254.3K
- PRQR 668.4K
- Earning Date
- EDD 01-01-0001
- PRQR 11-07-2024
- Dividend Yield
- EDD 7.52%
- PRQR N/A
- EPS Growth
- EDD N/A
- PRQR N/A
- EPS
- EDD N/A
- PRQR N/A
- Revenue
- EDD N/A
- PRQR $20,506,357.00
- Revenue This Year
- EDD N/A
- PRQR $298.83
- Revenue Next Year
- EDD N/A
- PRQR N/A
- P/E Ratio
- EDD N/A
- PRQR N/A
- Revenue Growth
- EDD N/A
- PRQR 306.68
- 52 Week Low
- EDD $4.22
- PRQR $1.18
- 52 Week High
- EDD $4.95
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- EDD 37.74
- PRQR 54.32
- Support Level
- EDD $4.78
- PRQR $3.57
- Resistance Level
- EDD $4.70
- PRQR $4.21
- Average True Range (ATR)
- EDD 0.06
- PRQR 0.24
- MACD
- EDD -0.00
- PRQR -0.08
- Stochastic Oscillator
- EDD 5.26
- PRQR 20.00
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.